Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2024)
Denali Therapeutics (DNLI) has disclosed Asset Utilization Ratio for 7 consecutive years, with 0.22 as the latest value for Q3 2024.
- On a quarterly basis, Asset Utilization Ratio rose 562.67% to 0.22 in Q3 2024 year-over-year; TTM through Sep 2024 was 0.22, a 562.67% increase, with the full-year FY2023 number at 0.25, up 10558.38% from a year prior.
- Asset Utilization Ratio was 0.22 for Q3 2024 at Denali Therapeutics, up from 0.21 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.3 in Q4 2023 to a low of 0.04 in Q2 2023.
- A 5-year average of 0.07 and a median of 0.03 in 2023 define the central range for Asset Utilization Ratio.
- Peak YoY movement for Asset Utilization Ratio: tumbled 141.9% in 2023, then surged 23477.75% in 2024.
- Denali Therapeutics' Asset Utilization Ratio stood at 0.01 in 2020, then skyrocketed by 511.88% to 0.03 in 2021, then plummeted by 85.56% to 0.0 in 2022, then soared by 7220.85% to 0.3 in 2023, then decreased by 28.42% to 0.22 in 2024.
- Per Business Quant, the three most recent readings for DNLI's Asset Utilization Ratio are 0.22 (Q3 2024), 0.21 (Q2 2024), and 0.24 (Q1 2024).